AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Gastric Cancer · Gastroesophageal Junction Cancer · Biliary Tract Cancer · Pancreatic Ductal Adenocarcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 226 (planned)
- Started
- Dec 13, 2023
- Main results expected
- Nov 17, 2026
- Fully finished
- Jun 28, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of adverse events (AEs), serious AEs (SAEs). Changes from baseline in clinical laboratory parameters, vital signs, ECGs and physical examination. Rate of AEs leading to discontinuation of AZD0901, Occurrence of DLTs.
Measured over: 30 days post treatment completion. AE Follow Up for 90 days post AZD0901 discontinuation.
Objective Response Rate (ORR).
Measured over: From date of first dose of AZD0901 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years).
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06219941 · record last updated 2026-09-30 · checked 2026-11-09 15:47 UTC